Tech Company Financing Transactions
Palvella Therapeutics Funding Round
Adams Street Partners, Agent Capital and BioAdvance Ventures participated in a $45 million Series C funding round for Palvella Therapeutics. The round closed on 6/1/2020.
Transaction Overview
Company Name
Announced On
6/1/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the capital for the advancement of PTX-022 (QTORIN 3.9% rapamycin anhydrous gel) for the treatment of adults with PC, a rare, chronically debilitating and lifelong genetic disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 Strafford Ave. 360
Wayne, PA 19087
USA
Wayne, PA 19087
USA
Phone
Website
Email Address
Not Recorded
Overview
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. We focus on developing therapies that specifically target the root cause of the disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wes Kaupinen
Chief Financial Officer
Kathleen McGowan
Chief Scientific Officer
Braham Shroot
Vice President
Jason Connor
VP - Engineering
Gregory Coulter
VP - Operations
Emily Cook
VP - Operations
Kathy Goin
Browse more venture capital transactions:
Prev: 6/1/2020: Trusscore venture capital transaction
Next: 6/1/2020: Yahaha Studios venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs